Research progress of bone-modifying agents in the treatment of bone metastases
10.3760/cma.j.issn.1673-422X.2014.03.021
- VernacularTitle:骨改良药治疗骨转移的研究进展
- Author:
Shanshan SUN
;
Yuemeng ZHANG
;
Yingjie GAO
;
Wencang GAO
- Publication Type:Journal Article
- Keywords:
Neoplasm metastases;
Diphosphonates;
Denosumab
- From:
Journal of International Oncology
2014;41(3):226-228
- CountryChina
- Language:Chinese
-
Abstract:
Bone-modifying agents (BMA) is a series drugs to alleviate the pain,pathological fractures,spinal cord compression,hypercalcemia,bone-related events which induced by bone metastases.Bisphosphonate drugs and denosumab are two dominant kinds of BMA at present.It has been proved that BMA is used in bone metastases patients with bone destruction,as adjuvant therapy for chemotherapy and radiotherapy,which can significantly improve the efficacy and prolong the survival of patients.In addition,some traditional Chinese medcine can effectively relieve a series of related symptoms caused by bone metastases and improve prognosis.Choosing right medication in clinical work can maximize the reduction of pain caused by bonerelated events and improve the quality of life of patients.
